AR043651A1 - Composicion farmaceutica dispersable para el tratamiento de mastitis y trastornos oticos - Google Patents

Composicion farmaceutica dispersable para el tratamiento de mastitis y trastornos oticos

Info

Publication number
AR043651A1
AR043651A1 ARP040100904A ARP040100904A AR043651A1 AR 043651 A1 AR043651 A1 AR 043651A1 AR P040100904 A ARP040100904 A AR P040100904A AR P040100904 A ARP040100904 A AR P040100904A AR 043651 A1 AR043651 A1 AR 043651A1
Authority
AR
Argentina
Prior art keywords
agent
pharmaceutical composition
organ
antibacterial agent
dispersable
Prior art date
Application number
ARP040100904A
Other languages
English (en)
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of AR043651A1 publication Critical patent/AR043651A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0046Ear
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0041Mammary glands, e.g. breasts, udder; Intramammary administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Método de tratamiento de un estado infeccioso en un órgano que contiene fluido que tiene un orificio exterior natural, tal como la ubre de un animal productor de leche o un oído. El método comprende administrar un agente antibacteriano al órgano a través del orificio exterior ya administrar con el agente antibacteriano en terapia de combinación un segundo agente que es un agente anti-inflamatorio, un analgésico y/o un antipirético. El agente antibacteriano y, opcionalmente, el segundo agente se administra como una composición farmacéutica que comprende adicionalmente un vehículo que comprende una aceite anfipático que es dispersable en agua e insoluble en etanol, cera microcristalina y un excipiente no acuoso aceptable farmacéuticamente. Se proporciona también una composición tal que comprende el agente antibacteriano y el segundo agente. La composición es fácilmente dispersable en el fluido del órgano que contiene fluido.
ARP040100904A 2003-03-20 2004-03-18 Composicion farmaceutica dispersable para el tratamiento de mastitis y trastornos oticos AR043651A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45620103P 2003-03-20 2003-03-20

Publications (1)

Publication Number Publication Date
AR043651A1 true AR043651A1 (es) 2005-08-03

Family

ID=33030090

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040100904A AR043651A1 (es) 2003-03-20 2004-03-18 Composicion farmaceutica dispersable para el tratamiento de mastitis y trastornos oticos

Country Status (19)

Country Link
US (1) US20040214753A1 (es)
EP (1) EP1608406A1 (es)
JP (1) JP2006520778A (es)
KR (1) KR100765614B1 (es)
CN (1) CN1761486A (es)
AR (1) AR043651A1 (es)
AU (1) AU2004222518A1 (es)
BR (1) BRPI0408559A (es)
CA (1) CA2519589A1 (es)
CL (1) CL2004000471A1 (es)
CO (1) CO5611165A2 (es)
MX (1) MXPA05010019A (es)
NO (1) NO20054777L (es)
NZ (1) NZ541780A (es)
RU (1) RU2321423C2 (es)
TW (1) TWI265809B (es)
UY (1) UY28236A1 (es)
WO (1) WO2004082719A1 (es)
ZA (1) ZA200506531B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020035107A1 (en) * 2000-06-20 2002-03-21 Stefan Henke Highly concentrated stable meloxicam solutions
DE10161077A1 (de) * 2001-12-12 2003-06-18 Boehringer Ingelheim Vetmed Hochkonzentrierte stabile Meloxicamlösungen zur nadellosen Injektion
US8992980B2 (en) * 2002-10-25 2015-03-31 Boehringer Ingelheim Vetmedica Gmbh Water-soluble meloxicam granules
AU2003299574A1 (en) * 2002-12-02 2004-06-23 Byocoat Llc Composition ad method for treating plant fungal disease
JP4691018B2 (ja) 2003-03-05 2011-06-01 ビオコート エンタープライジズ, インコーポレイテッド 抗菌溶液およびプロセス
EP1568369A1 (en) * 2004-02-23 2005-08-31 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the treatment of respiratory diseases in pigs
DE602005002742T2 (de) * 2004-04-22 2008-01-24 Pfizer Products Inc., Groton Verfahren zur stabilisierung von ungeordnetem cefovecin-natriumsalz
DE102004021281A1 (de) * 2004-04-29 2005-11-24 Boehringer Ingelheim Vetmedica Gmbh Verwendung von Meloxicam-Formulierungen in der Veterinärmedizin
DE102004030409A1 (de) * 2004-06-23 2006-01-26 Boehringer Ingelheim Vetmedica Gmbh Neue Verwendung von Meloxicam in der Veterinärmedizin
US7858115B2 (en) * 2004-06-24 2010-12-28 Idexx Laboratories Phospholipid gel compositions for drug delivery and methods of treating conditions using same
US7854943B2 (en) * 2004-06-24 2010-12-21 Idexx Laboratories Phospholipid gel compositions for drug delivery and methods of treating conditions using same
US7618651B2 (en) * 2004-06-24 2009-11-17 Idexx Laboratories Pharmaceutical compositions for drug delivery and methods of treating or preventing conditions using same
DE102005055385A1 (de) * 2004-12-09 2006-06-14 Bayer Healthcare Ag Arzneimittel zur hygienischen Applikation im Ohr
AT501376B1 (de) * 2005-01-17 2010-11-15 Pregenzer Bruno Glucokortikoid-hältiges arzneimittel
WO2007039417A1 (en) * 2005-09-30 2007-04-12 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical preparation containing meloxicam
US20070264296A1 (en) * 2006-05-10 2007-11-15 Myntti Matthew F Biofilm extracellular polysachharide solvating system
US7976873B2 (en) 2006-05-10 2011-07-12 Medtronic Xomed, Inc. Extracellular polysaccharide solvating system for treatment of bacterial ear conditions
US7993675B2 (en) 2006-05-10 2011-08-09 Medtronic Xomed, Inc. Solvating system and sealant for medical use in the sinuses and nasal passages
US7959943B2 (en) 2006-05-10 2011-06-14 Medtronics Xomed, Inc. Solvating system and sealant for medical use in the middle or inner ear
WO2008035370A2 (en) * 2006-07-10 2008-03-27 Advanced Enzyme Technologies Limited Compositions for prevention and treatment of mastitis and metritis
US8088095B2 (en) 2007-02-08 2012-01-03 Medtronic Xomed, Inc. Polymeric sealant for medical use
KR101421765B1 (ko) * 2007-02-08 2014-07-22 메드트로닉 좀드 인코퍼레이티드 의료용 용매화 시스템 및 실런트
BRPI0700969A (pt) * 2007-03-22 2008-11-04 Ouro Fino Participacoes E Empr composição para o tratamento de afecções bacterianas e inflamatórias em animais de companhia
US20100298386A1 (en) * 2007-10-03 2010-11-25 Burwell Steven R Compositions and methods for treating mastitis
AU2009257390B2 (en) 2008-06-12 2014-09-04 Medtronic Xomed, Inc. Method for treating chronic wounds with an extracellular polymeric substance solvating system
US8318817B2 (en) * 2008-07-21 2012-11-27 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
WO2010042427A2 (en) 2008-10-06 2010-04-15 Microbial Defense Systems, Llc Antimicrobial composition and methods of making and using same
CN101953784B (zh) * 2009-07-16 2012-02-08 中国农业大学 含阿莫西林、硫酸粘菌素和泼尼松龙的兽用混悬液及其制备方法
CN102647971B (zh) * 2009-10-12 2016-03-16 贝林格尔.英格海姆维特梅迪卡有限公司 用于包含美洛昔康的组合物的容器
WO2011107150A1 (en) 2010-03-03 2011-09-09 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats
US9795568B2 (en) 2010-05-05 2017-10-24 Boehringer Ingelheim Vetmedica Gmbh Low concentration meloxicam tablets
JP6463629B2 (ja) 2011-05-10 2019-02-06 ネクスト サイエンス アイピー ホールディングス ピーティワイ エルティーディ 抗菌性固体およびその製造方法
BRPI1103782A2 (pt) * 2011-08-19 2013-07-30 Eurofarma Lab Ltda produto veterinÁrio para tratamento de mastite, pre composiÇço antibiàtica a anti inflamatària, kit, mÉtodo de preparaÇço uso e mÉtodo de tratamento de mastite
CN102784161A (zh) * 2012-08-01 2012-11-21 张吉川 一种治疗急慢性中耳炎的特效滴耳液
US10195153B2 (en) 2013-08-12 2019-02-05 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
EP3209282A4 (en) 2014-10-20 2018-05-23 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
CN104825474B (zh) * 2015-04-30 2018-02-06 中国农业科学院兰州畜牧与兽药研究所 一种治疗动物体表损伤的药物组方及其制备工艺
CA2984614C (en) * 2015-05-06 2020-07-14 Zoetis Services Llc Hydrogel formulation with mild adhesion
US10434097B1 (en) 2015-09-14 2019-10-08 Gateway Biotechnology, Inc. Methods and compositions for treating hearing disorders
EP3436054B2 (en) 2016-09-13 2022-07-27 Allergan, Inc. Stabilized non-protein clostridial toxin compositions
CN107252441A (zh) * 2017-08-07 2017-10-17 咸阳职业技术学院 一种治疗奶牛乳腺炎的药物组合物及其制备方法
WO2019126783A1 (en) * 2017-12-22 2019-06-27 Otonomy, Inc. Triglyceride otic formulations and uses thereof
KR102671650B1 (ko) * 2019-03-06 2024-06-04 조에티스 서비시즈 엘엘씨 바로 사용가능한 주사가능한 제형
CA3152497A1 (en) * 2019-08-27 2021-03-04 Kashiv Biosciences, Llc Compounds useful to treat pain

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3636194A (en) * 1969-10-23 1972-01-18 Douglas G Parizeau Composition and method for treating mastitis with therapeutic agents
DE2063896A1 (de) * 1970-12-28 1972-07-20 Dynamit Nobel Ag, 5210 Troisdorf Salbengrundlagen auf der Basis von Triglyceriden gesättigter mittelkettiger Fettsäuren und Verfahren zu deren Herstellung
ES2079994B1 (es) * 1992-10-07 1996-08-01 Cusi Lab Formulacion farmaceutica a base de polimixina-trimetoprim y un agente antiinflamatorio para su utilizacion topica oftalmica y otica.
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
RU2169143C2 (ru) * 1995-05-25 2001-06-20 Джи. Ди. Сирл Энд Ко. Способ получения 3-галогеналкил-1н-пиразолов
NZ309624A (en) * 1995-06-06 1999-04-29 Bayer Ag Non-irritating, non-sensitizing, non-ototoxic (harmful to the ears) antibacterial compositions
US5756529A (en) * 1995-09-29 1998-05-26 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies
AP9700912A0 (en) * 1996-01-11 1997-01-31 Smithkline Beecham Corp Novel cycloalkyl substituted imidazoles
RO121338B1 (ro) * 1996-04-12 2007-03-30 G.D. Searle & Co. Derivaţi de benzensulfonamidă, procedeu de preparare a acestora, compoziţie farmaceutică şi utilizarea ca inhibitori de cox-2
US5736151A (en) * 1996-12-09 1998-04-07 Pharmacia & Upjohn Company Antibiotic oil suspensions
US6307047B1 (en) * 1997-08-22 2001-10-23 Abbott Laboratories Prostaglandin endoperoxide H synthase biosynthesis inhibitors
US6509327B1 (en) * 1998-09-30 2003-01-21 Alcon Manufacturing, Ltd. Compositions and methods for treating otic, ophthalmic and nasal infections
AR020660A1 (es) * 1998-09-30 2002-05-22 Alcon Lab Inc Composiciones antibioticas para el tratamiento de ojos, oidos y nariz
US6395746B1 (en) * 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
US6440964B1 (en) * 1998-09-30 2002-08-27 Alcon Manufacturing, Ltd. Compositions and methods for treating ophthalmic and otic infections
US7064132B2 (en) * 1999-11-28 2006-06-20 Scientific Development And Research, Inc. Composition and method for treatment of otitis external
US6676930B2 (en) * 1999-11-28 2004-01-13 Scientific Development And Research, Inc. Composition and method for treatment of otitis media
NZ519781A (en) * 1999-12-23 2004-04-30 Nitromed Inc Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
US20010049366A1 (en) * 2000-02-09 2001-12-06 Alcon Universal Ltd. Topical solution formulations containing an antibiotic and a corticosteroid
AU2001251011A1 (en) * 2000-03-27 2001-10-08 The General Hospital Corporation Treatments for immune-mediated ear disorders
EP1712239A3 (en) * 2000-05-12 2007-08-22 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
CA2409123A1 (en) * 2000-06-08 2001-12-13 The University Of Texas System Heterocycle derivatives and methods of use
DE60131537T2 (de) * 2000-06-22 2008-10-23 Nitromed, Inc., Lexington Nitrosierte und nitrosylierte taxane, zubereitungen und methoden der verwendung
US7842791B2 (en) * 2002-12-19 2010-11-30 Nancy Jean Britten Dispersible pharmaceutical compositions

Also Published As

Publication number Publication date
UY28236A1 (es) 2004-11-08
US20040214753A1 (en) 2004-10-28
CA2519589A1 (en) 2004-09-30
EP1608406A1 (en) 2005-12-28
NZ541780A (en) 2008-06-30
CO5611165A2 (es) 2006-02-28
WO2004082719A1 (en) 2004-09-30
AU2004222518A1 (en) 2004-09-30
JP2006520778A (ja) 2006-09-14
RU2321423C2 (ru) 2008-04-10
ZA200506531B (en) 2006-11-29
CL2004000471A1 (es) 2005-04-22
KR100765614B1 (ko) 2007-10-09
RU2005126363A (ru) 2006-05-10
KR20050114245A (ko) 2005-12-05
TW200507852A (en) 2005-03-01
BRPI0408559A (pt) 2006-03-21
NO20054777L (no) 2005-10-17
MXPA05010019A (es) 2005-11-17
TWI265809B (en) 2006-11-11
CN1761486A (zh) 2006-04-19

Similar Documents

Publication Publication Date Title
AR043651A1 (es) Composicion farmaceutica dispersable para el tratamiento de mastitis y trastornos oticos
UY28235A1 (es) Formulación dispersable de un agente antiinflamatorio
CO5650245A2 (es) Formulaciones dispersable de un agente anti-inflamatorio
AR042537A1 (es) Composiciones farmaceuticas dispersables que contienen antibacterianos para animales productores de leche
AR026165A1 (es) Dispositivo para la administracion de drogas.
WO2007072503A3 (en) Combinations for managing inflammation and associated disorders
BRPI0512311A (pt) uso de meloxicam em medicina veterinária para o tratamento de doenças inflamatórias dolorosas
MY144292A (en) Method of reducing oral tissue inflammation using magnolia extract
AR058679A1 (es) Preparacion farmaceutica que contiene meloxicam
US5888523A (en) Topical non-steroidal anti-inflammatory drug composition
MD2516B1 (en) Anti-inflammatory, antiseptic and antimycotic medicament in the form of gel
CN104888339A (zh) 一种妇炎栓剂推进器
CN204637276U (zh) 一种妇炎栓剂推进器
CN108186546A (zh) 一种阴部洗剂及其制备方法
CA2515259A1 (en) Use of acetylsalicylic acid for the treatment of hemorrhoidal disease
BRPI0414223A (pt) uso de extratos de gentiana lutea como um agente antimicrobiano
PE20141530A1 (es) Composicion farmaceutica para uso en inflamacion y dolor
ES2372193B1 (es) Dispositivo intravaginal para tratamiento con oxígeno-ozono.
RU2004100547A (ru) Лечебный гель "пиявит+" на основе биологически активных веществ, продуцируемых медицинской пиявкой и способ его получения
CN104623746A (zh) 一体化带气囊肛管引流器
TH10572C3 (th) เจลปิดเนื้อเยื่อในฟัน
ES2172818T3 (es) Uso de antagonistas de lh-rh como agente de diagnostico.
CN102232820A (zh) 一种医用消毒装置
TH10572A3 (th) เจลปิดเนื้อเยื่อในฟัน
BR0205625C1 (pt) Formulações nasais em gel

Legal Events

Date Code Title Description
FA Abandonment or withdrawal